Colorectal cancer in Vietnam is the 4th most common cancer in men and the 3rd most common cancer in women. In Ho Chi Minh City alone, the total number of new cases of colorectal-anal cancer in both sexes and all age groups in 2 years was 2,626. When cancer is in the distant metastasis stage, the 5-year survival rate is only 15.7%.
With the advancement of medicine, anti-EGFR therapy has been used clinically for 20 years since this therapy was approved by the European Medicines Agency for the treatment of colorectal cancer (in 2004).
At the Conference, many studies showed that in patients with metastatic colorectal cancer who are no longer able to undergo surgery, individualizing treatment with anti-EGFR therapy based on gene mutation status can help increase survival time to over 30 months.
On the same day, Ho Chi Minh City Oncology Hospital and Merck Healthcare Vietnam Co., Ltd. officially signed a memorandum of understanding on cooperation. This event marks an important step forward in improving the quality of treatment and care for cancer patients.
